AroCell is approved for listing on the Nasdaq First North and publishes Corporate description

AroCell AB (publ) has been accepted for trading on Nasdaq First North. The last day of trading on AktieTorget is the 29 June 2016 and the first day of trading on Nasdaq First North is the 30 June 2016.

AroCell will continue to be traded under the ticker symbol AROC with current ISIN code SE0003883990. Redeye AB will act as the company's Certified Adviser on First North. The company has established a corporate description approved by Nasdaq First North, which from today is available on the AroCells website, www.arocell.com.

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706 926206
info@arocell.com
www.arocell.com

About AroCell
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com . AroCell (AROC) is listed at AktieTorget and has about 2 800 shareholders.